Lisa Shirreff
A5064067009- SARS-CoV-2 and COVID-19 Research
- Immunotherapy and Immune Responses
- COVID-19 Clinical Research Studies
- HIV Research and Treatment
- SARS-CoV-2 detection and testing
- Mycobacterium research and diagnosis
- Animal Virus Infections Studies
- Genomics and Phylogenetic Studies
- Viral Infections and Immunology Research
- Tuberculosis Research and Epidemiology
- Immune Cell Function and Interaction
- Immune responses and vaccinations
- Long-Term Effects of COVID-19
- HIV/AIDS Research and Interventions
- interferon and immune responses
- Virology and Viral Diseases
- Monoclonal and Polyclonal Antibodies Research
- Influenza Virus Research Studies
- Reproductive System and Pregnancy
- Animal Disease Management and Epidemiology
- Immune Response and Inflammation
- Virus-based gene therapy research
- Inhalation and Respiratory Drug Delivery
- Orthopedic Infections and Treatments
University of Louisiana at Lafayette
2018-2024
While the rapid development of COVID-19 vaccines has been a scientific triumph, need remains for globally available vaccine that provides longer-lasting immunity against present and future SARS-CoV-2 variants concern (VOCs). Here, we describe DCFHP, ferritin-based, protein-nanoparticle candidate that, when formulated with aluminum hydroxide as sole adjuvant (DCFHP-alum), elicits potent durable neutralizing antisera in non-human primates known VOCs, including Omicron BQ.1, well SARS-CoV-1....
Despite the remarkable efficacy of COVID-19 vaccines, waning immunity and emergence SARS-CoV-2 variants such as Omicron represents a global health challenge. Here, we present data from study in nonhuman primates demonstrating durable protection against BA.1 variant induced by subunit vaccine comprising receptor binding domain ancestral strain (RBD-Wu) on I53-50 nanoparticle adjuvanted with AS03, which was recently authorized for use individuals 18 years or older. Vaccination neutralizing...
The rapid emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that evade immunity elicited by vaccination has placed an imperative on the development countermeasures provide broad protection against SARS-CoV-2 and related sarbecoviruses. Here, we identified extremely potent monoclonal antibodies (mAbs) neutralized multiple sarbecoviruses from macaques vaccinated with AS03-adjuvanted monovalent subunit vaccines. Longitudinal analysis revealed progressive...
Adolescents are a growing population of people living with HIV. The period between weaning and sexual debut presents low-risk window for HIV acquisition, making early childhood an ideal time implementing immunization regimen. Because the elicitation broadly neutralizing antibodies (bnAbs) is critical effective vaccine, our goal was to assess ability bnAb B cell lineage-designed envelope SOSIP (protein stabilized by disulfide bond gp120-gp41-named "SOS"-and isoleucine-to-proline point...
Eliciting potent and broadly neutralizing antibodies (bnAbs) is a major goal in HIV-1 vaccine development. Here, we describe how germline-targeting immunogen BG505 SOSIP germline trimer 1.1 (GT1.1), generated through structure-based design, engages diverse range of VRC01-class bnAb precursors. A single immunization with GT1.1 expands CD4 binding site (CD4bs)–specific B cells knock-in mice drives maturation. In nonhuman primates (NHPs), primes CD4bs-specific serum responses. Selected...
Authorization of the Matrix-M (MM)–adjuvanted R21 vaccine by three countries and its subsequent endorsement World Health Organization for malaria prevention in children are a milestone fight against malaria. Yet, our understanding innate adaptive immune responses elicited this remains limited. Here, we compared clinically relevant adjuvants [3M-052 + aluminum hydroxide (Alum) (3M), TLR7/8 agonist formulated Alum; GLA-LSQ, TLR4 liposomes with QS-21; MM, now-approved adjuvant R21] their...
Abstract Mycobacterium marinum is the causative agent for tuberculosis-like disease mycobacteriosis in fish and skin lesions humans. Ubiquitous its geographical distribution, M . known to occupy diverse as hosts. However, information about genomic diversity limited. Here, we provide genome sequences 15 strains isolated from infected humans fish. Comparative analysis of these four available genomes M, E11, MB2 Europe reveal high among strains, leading conclusion that should be divided into...
TGF-β plays a critical role in maintaining immune cells resting state by inhibiting cell activation and proliferation. Resting HIV-1 target represent the main cellular reservoir after long-term antiretroviral therapy (ART). We hypothesized that releasing from TGF-β–driven signaling would promote latency reversal. To test our hypothesis, we compared models with without type 1 receptor inhibitor, galunisertib. tested effect of galunisertib SIV-infected, ART-treated macaques monitoring SIV-env...
Abstract The development of a portfolio SARS-CoV-2 vaccines to vaccinate the global population remains an urgent public health imperative. Here, we demonstrate capacity subunit vaccine under clinical development, comprising Spike protein receptor binding domain displayed on two-component nanoparticle (RBD-NP), stimulate robust and durable neutralizing antibody (nAb) responses protection against in non-human primates. We evaluated five different adjuvants combined with RBD-NP including Essai...
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 has led to the development a large number vaccines, several which are now approved for use humans. Understanding vaccine-elicited antibody responses against emerging SARS-CoV-2 variants concern (VOCs) real time is key inform public health policies. Serum neutralizing titers current best correlate protection from challenge non-human primates and metric understand immune evasion VOCs. We report that...
Abstract Members of the Mycobacterium chelonae - abscessus complex (MCAC) are close to mycobacterial ancestor and includes both human, animal fish pathogens. We present genomes 14 members this complex: complete salmoniphilum type strains, seven M. isolates, five -like strains including isolated during an outbreak in facility at Uppsala University. Average nucleotide identity (ANI) analysis core gene phylogeny revealed that variants human pathogen franklinii phylogenetically . Our data...
While the rapid development of COVID-19 vaccines has been a scientific triumph, need remains for globally available vaccine that provides longer-lasting immunity against present and future SARS-CoV-2 variants concern (VOCs). Here, we describe DCFHP, ferritin-based, protein-nanoparticle candidate that, when formulated with aluminum hydroxide as sole adjuvant (DCFHP-alum), elicits potent durable neutralizing antisera in non-human primates known VOCs, including Omicron BQ.1, well SARS-CoV-1....
The rapid emergence of SARS-CoV-2 variants that evade immunity to vaccination has placed a global health imperative on the development therapeutic countermeasures provide broad protection against and related sarbecoviruses. Here, we identified extremely potent pan-sarbecovirus antibodies from non-human primates vaccinated with an AS03 adjuvanted subunit vaccine recognize conserved epitopes in receptor binding domain (RBD) femtomolar affinities. Longitudinal analysis revealed progressive...
VRC01 protects macaques from vaginal SHIV infection after a single high-dose challenge. Infusion of simianized anti-α4β7 mAb (Rh-α4β7) just prior to, and during repeated exposures to SIVmac251 partially protected SIV rescued CD4+ T cells. To investigate the impact combining Rh-α4β7 on infection, 3 groups were treated with suboptimal dosing alone or in combination control antibodies initiation weekly high dose (1000 TCID50) SHIVAD8-EO. The Rh-α4β7-VRC01 significantly delayed SHIVAD8-EO...
Summary Despite the remarkable efficacy of COVID-19 vaccines, waning immunity, and emergence SARS-CoV-2 variants such as Omicron represents a major global health challenge. Here we present data from study in non-human primates demonstrating durable protection against BA.1 variant induced by subunit vaccine, consisting RBD (receptor binding domain) on I53-50 nanoparticle, adjuvanted with AS03, currently Phase 3 clinical trial ( NCT05007951 ). Vaccination robust neutralizing antibody (nAb)...
A vaccine that can achieve protective immunity prior to sexual debut is critical prevent the estimated 410,000 new HIV infections occur yearly in adolescents. As children living with make broadly neutralizing antibody (bnAb) responses plasma at a faster rate than adults, early childhood an opportune window for implementation of multi-dose immunization strategy elicit adolescence. Therefore, goal our study was assess ability B cell lineage-designed envelope SOSIP induce bnAbs life. Infant...
Abstract The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019 has led to the development a large number vaccines, several which are now approved for use humans. Understanding vaccine-elicited antibody responses against emerging SARS-CoV-2 variants concern (VOC) real time is key inform public health policies. Serum neutralizing titers current best correlate protection from challenge non-human primates and metric understand immune evasion VOC. We report that...